-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Piper Sandler Maintains Overweight on TCR2 Therapeutics, Raises Price Target to $10

Benzinga · 01/06/2023 06:38
Piper Sandler analyst Do Kim maintains TCR2 Therapeutics (NASDAQ:TCRR) with a Overweight and raises the price target from $8 to $10.